Both the estrogen receptor (ER) and the progesterone receptor (PR) have two subtypes: ER-a and b, and PR-A and -B, respectively. These subtypes dier in function and expression, and recent reports have correlated changes in the normal proportions of these isoforms with neoplastic states. We investigated ER and PR isoform expression in normal pre-and post-menopausal endometrium, well-dierentiated endometrial adenocarcinoma, and poorly dierentiated malignant mixed mullerian tumors (MMMTs). Semi-quantitative RT ± PCR and immunoblotting were used to measure receptor mRNA and protein expression. Estrogen receptor-a/b mRNA ratios were signi®cantly higher in postmenopausal (27.3) compared to premenopausal endometrium (4.9) mainly as a result of lower ER-b expression in the former. Compared to age-matched postmenopausal controls, the ER-a/b ratio was reduced in both grade I adenocarcinoma and MMMT specimens (3.3 and 6.8, respectively), due to a selective loss of ER-a. The relative abundance of PR-A and PR-B mRNA remained unchanged between all tissue subtypes. Total PR protein, however, was signi®cantly reduced in MMMTs compared to all other groups. Thus, sex steroid receptor expression is signi®cantly and dierentially altered in well-dierentiated and poorly-dierentiated endometrial cancers. Both cancers exhibit decreased ER-a expression and the MMMTs also demonstrate a signi®cant loss of PR protein. Oncogene (2001) 20, 6965 ± 6969. 
Epidemiological studies have identi®ed exogenous and endogenous estrogen excess states as major risk factors for the development of endometrial adenocarcinoma and its precursors (Fechner and Kaufman, 1974; Gusberg and Kardon, 1971; Gray et al., 1977; Antunes et al., 1979) . Progesterone has been shown to be eective in preventing and even reversing the glandular proliferation induced by unopposed estrogen (Persson et al., 1989) . In contrast to adenocarcinomas, malignant mixed mullerian tumors (MMMT), which comprise approximately 5% of all endometrial cancers, are poorly dierentiated, hormonally unresponsive, and clinically more aggressive with a worse prognosis (Soper et al., 1984; Sutton et al., 1986) . However, MMMTs are associated with many of the same epidemiological risk factors that have implicated unopposed estrogen exposure as a risk factor for adenocarcinomas, and these tumors are thought to share a common etiology (Zelmanowicz et al., 1998) .
The exact mechanism for estrogen's proliferative eects on the endometrium and its role in neoplasia remain unknown. Estrogen's cellular actions are mediated through the estrogen receptor (ER), a member of the ligand activated nuclear transcription factor superfamily (Evans, 1988) . Much of the investigation on mechanisms of action of ER in the endometrium has been performed on ER-a, and relatively little is known about cellular pathways involving the recently discovered ER-b (Enmark et al., 1997; Matsuzaki et al., 1999) The traditional hypothesis for ER action consists of transcriptional activation resulting from the binding of the ER-ligandcoactivator complex to speci®c DNA sequences called estrogen response elements (ERE). An alternate and cell-speci®c pathway for ER action involving the activating protein-1 (AP-1) binding site has recently been described (Umayahara et al., 1994; Philips et al., 1993) . Estrogen receptor-a and ER-b have been shown to have opposite eects on transcription at the AP-1 site (Paech et al., 1997) . The net action of estrogen or selective estrogen response modulators on gene expression and ultimately proliferation in any given tissue may depend not only on the promoter context, but also on the relative distribution of ER-a and -b. In support of this hypothesis, Pujol et al. (1998) recently observed Oncogene (2001) 20, 6965 ± 6969 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc that while ER-b was the predominant isoform in normal ovary, ER-a was markedly elevated in ovarian carcinoma, with 60% of these samples exhibiting an ER-a : ER-b mRNA ratio of greater than 1. These authors concluded that over expression of ER-a compared to ER-b may be a marker of ovarian carcinogenesis. In addition to con®rming ER-b as the predominant ER subtype in normal ovary (Rutherford et al., 2000; Brandenberger et al., 1998) , other investigators have found only ER-a present in metastatic foci of ovarian cancer (Rutherford et al., 2000) . Our laboratory recently reported a selective loss of ER-b protein in malignant human colon when compared to adjacent normal colonic tissue (Foley et al., 2000) .
The progesterone receptor has also been implicated in the development of endometrial cancer. Progesterone's cellular eects are mediated by its two receptors PR-A and PR-B, and a decrease in PR-B has been observed in poorly dierentiated endometrial cancer cell-lines and in some breast tumors (Kumar et al., 1998; Graham et al., 1996) . These observations point to an association between malignant states and disturbances in the relative abundance of ER and PR subtypes. Our hypothesis is that a similar pattern of dierential ER or PR subtype expression may distinguish endometrial cancer from normal endometrium. Furthermore, such preferential expression may explain why adenocarcinomas tend to be responsive to hormonal treatment while MMMTs are not. In this study we compared the relative amounts of ER and PR isoform expression in human endometrial samples from pre-and postmenopausal patients, as well as in well-dierentiated endometrial adenocarcinoma and MMMT tumors.
We began by comparing ER-a to ER-b mRNA ratios between normal premenopausal and postmenopausal endometrium (Figure 1a) . The mean ER-a/b ratio increased from 4.9 in premenopausal samples to 27.3 in normal postmenopausal endometrium Figure 1 Semi-quantitative analysis of ER-a and ER-b mRNA expression using b-2-microglobulin (b2m) mRNA as an internal control. Endometrial tissue was obtained with IRB approval at the time of hysterectomy and immediately frozen in liquid nitrogen. The mean age and standard deviation (in parentheses) of patients in the premenopausal, postmenopausal, adenocarcinoma, and MMMT groups were 38 (5.1), 58 (4.8), 59 (3.9), and 64 (5.3), respectively. Comparison of ER-a and ER-b mRNA using sqRT ± PCR was carried out using a protocol and primers described previously (Foley et al., 2000) . Total PR and PR-B were ampli®ed using two sets of primers. The ®rst set, PR common, (5'-ACAGAATTCATGAGCCGGTCCGGGTGCA-AG-3' and 5'-ACAAGATCTCCACCCAGAGCCCGAGGTTT-3') ampli®ed a region common to both PR-A and PR-B while the second set, PR-B, (5'-ACAGAATTCATGACTGAGCTGAAGGCAAAG-GGT-3' and 5'-ACAAGATCTCAAACAGGCACCAAGAG-CTGCTGA-3') ampli®ed a region unique to PR-B. In all sqRT ± PCR experiments b2m was used as an internal control. Ratios of ER-a and ER-b to b2m and PR-B to PR common were calculated using ImageQuant densitometry software (Molecular Dynamics, Sunnyvale, CA, USA). PR-A mRNA levels were inferred using PR-B and total PR mRNA values. The number of samples in each group appears in parentheses and error-bars re¯ect+s.e. The units are fold expression compared to b2m. The Student t-test was used for statistical comparison between patient groups. A chance probability of less than 0.05 was considered signi®cant, and the P values do not re¯ect any correction for multiple comparisons. (Figure 1c) . We then compared ER-a/b mRNA ratios in normal endometrial samples to those observed in two dierent types of uterine tumors: the hormoneresponsive well-dierentiated (grade I) endometrioid adenocarcinomas and the hormone-resistant, poorly dierentiated MMMT. Both MMMT and grade I adenocarcinoma samples had ER-a/b mRNA ratios which were signi®cantly reduced compared to that seen in the age-matched, normal postmenopausal samples (P50.05, Figure 1a ). This reduction in the ER-a/b mRNA ratio was due to signi®cantly lower ER-a mRNA expression in both endometrial cancer groups (Figure 1b) .
Other investigators have reported that reduced or absent PR-B expression portends a poorly dierentiated endometrial cancer phenotype (Kumar et al., 1998) . However, this conclusion was based on observations in cell-lines and no information regarding in vivo tumor PR expression is available to date. The results of our sqRT ± PCR investigation of PR mRNA expression are shown in Figure 2 . These experiments revealed no statistical dierence in the PR-B/total PR mRNA ratios between proliferative premenopausal, normal postmenopausal endometrium, grade I adenocarcinoma, and MMMTs (Figure 2b ). Of note, 1 grade I adenocarcinoma sample contained very little PR-A or PR-B mRNA and one MMMT sample expressed only PR-A (Figure 2c ). These samples were excluded from PR subtype ratio calculations.
While the relative abundance of PR-B mRNA remained constant in all four endometrial tissue types, total PR mRNA expression (as indicated by thePR common/b2M mRNA ratio) was signi®cantly higher in MMMT (16.8) and grade I adenocarcinoma samples (21.3) compared to normal postmenopausal endometrium (5.5) (P50.001). The total PR mRNA expression in cancer groups were, however, signi®cantly lower than that of proliferative endometrium (21.3 versus 60 P50.001). Among the endometrial cancer specimens the PR/b2M mRNA ratio in MMMTs was lower than that of grade I adenocarcinomas (16.8 and 25.3, respectively), however, due to our small sample size this dierence did not reach statistical signi®cance (P=0.43, Figure 2a) .
In order to investigate receptor subtype protein expression two randomly selected patients from each group were selected for Western blot analysis (Figure  3a ± c) . These results were consistent with the relative abundance of ER and PR subtypes observed at the mRNA level in pre-and postmenopausal groups. However, the PR protein expression in MMMTs (Figure 3c ) was much lower than the corresponding mRNA level, as indicated by sqRT ± PCR. This loss of PR was further investigated by performing Western blot analysis on additional grade I and MMMT tumor samples. This experiment con®rmed the presence of very low to undetectable levels of PR protein in MMMTs and signi®cantly higher PR levels in grade I adenocarcinomas (Figure 3d) . The discrepancy between mRNA and protein levels of PR in MMMTs points to a post-transcriptional regulatory process in these tumors. Such a process may consist of changes in the rate of protein translation and/or degradation. Posttranscriptional regulation of nuclear receptors in normal and cancer tissues has been previously described by several investigators (Ing et al., 1996; Yeap et al., 1999; Alarid et al., 1999) . In agreement with these reports, we have observed that ER-b is posttranscriptionally down-regulated in colon cancer (Foley et al., 2000) . It is interesting that this apparent posttranscriptional down regulation of PR is limited to the poorly dierentiated MMMTs. Whether this contributes to or results from the poorly dierentiated phenotype of these tumors remains unknown. Future studies aimed at determining if in vitro overexpression of PR is capable of altering the poorly dierentiated phenotype would greatly increase our understanding of the signi®cance of lower PR expression in poorly dierentiated endometrial cancers. Our results demonstrate signi®cant dierences in the ER-a/b mRNA ratios and protein expression between normal endometrium and endometrial carcinoma, as well as between premenopausal and postmenopausal normal endometrium. The ER a/b mRNA ratios in both adenocarcinomas and MMMTs were much lower than that of the age-matched postmenopausal controls, resulting from a selective and signi®cant reduction in ER-a expression only. Western blot analysis con®rmed this loss of ER-a at the protein level. We also discovered a selective decrease in ER-b in the endometria of postmenopausal women. Since ER-b has been shown to act as a dominant negative regulator of ER-a action (Hall and McDonnell, 1999; Pettersson et al., 2000) , postmenopausal endometrium may be more sensitive to estrogenic compounds through unopposed ER-a action. This susceptibility to estrogenic eects may be further potentiated by the decreased total PR expression in this tissue (Figure 3) which signi®cantly reduces the regulatory impact of progesterone on uterine proliferation. These events would sensitize the postmenopausal endometrium toward estrogen-induced proliferation, and create a physiologic background in which neoplastic changes would be more likely to occur. This may explain why endometrial cancer is mainly a disease of postmenopausal women.
These observed loss of ER-a mRNA and protein in two histologically and clinically dierent endometrial tumors adds to an increasing body of evidence implicating abnormal ER-a/b ratios in neoplastic states. Cancers of ovary, colon, and endometrium are all characterized by a relative loss of the normally predominant ER subtype. In the ovary and colon, ERb is the predominant isoform (Pujol et al., 1998; Brandenberger et al., 1998; Foley et al., 2000) , while in the endometrium, ER-a is the main subtype (Matsuzaki et al., 1999) . The functional signi®cance of these changes remains to be elucidated. However, it is known that ER-a and ER-b form heterodimers (Cowley et al., 1997) , and that ER-b acts as an inhibitory modulator of ER-a stimulated ERE-dependent transcription and other biological responses (Hall and McDonnell, 1999; Pettersson et al., 2000) . Thus, an imbalance in the expression of either receptor would lead to changes in ER-mediated gene transcription, which are likely to aect cell proliferation. If alterations of ER-a/ER-b ratio impart a positive eect on cell-cycle progression, cells harboring such ER subtype imbalance may be unable to repair genetic and epigenetic DNA damage which requires checkpoint activation and cell-cycle arrest. These cells would therefore accumulate mutations over time. Thus in this model, cells with aberrant ER subtype expression would not only have a growth advantage, but would also be at increased risk for acquiring transforming mutations. Alternatively, a direct deleterious eect on the DNA damage repair process resulting from alterations of ER-a/ER-b ratio would produce the same risk for accumulating mutations and for the possible development of neoplasia. However, such a role has yet to be described for either ER isoform. Finally, to be signi®cant in neoplasia ER isoform dysregulation would have to occur in somatic stem cells responsible for epithelial renewal, since other epithelial cells are continuously shed, at least in the colon and the endometrium.
The comparison between poorly-dierentiated MMMT and the well-dierentiated adenocarcinomas showed no dierences in terms of ER subtype mRNA or protein expression levels. However, MMMT samples showed reduced total PR mRNA and protein compared to grade I adenocarcinomas. As discussed above, this loss of PR protein in MMMTs is likely to involve post-transcriptional changes. Furthermore, our in vivo ®ndings are in contrast to previous observations in endometrial cancer cell lines where a selective down regulation of PR-B was associated with poorly dierentiated endometrial cancer (Kumar et al., 1998) . While we did not see a selective loss of PR-B, the observed reduction of total PR may contribute to Figure 3 Endometrial ER and PR isoform protein expression in selected premenopausal (pre), postmenopausal (post), and grade I adenocarcinoma (Gr I) and MMMT samples. The methods for tissue processing, protein extraction, and immunoblotting were identical to those previously described (Jazaeri et al., 1999) . ER-a was detected using the 1D5 anti-human mouse monoclonal antibody (1 : 100 Dako Corporation, Carpinteria, CA, USA). ER-b was detected using the anti-human rabbit polyclonal antibody directed against amino acids 46 ± 63 of the human ERb (1 : 1000 Upstate Biotechnology, Lake Placid, NY, USA). PR-A and PR-B were detected using the anti-human mouse monoclonal antibody 1294/H9 (1 ug/ml) kindly provided by Dean P Edwards, University of Colorado Health Science Center. Each immunoblot was then incubated in the appropriate horseradish peroxidaselabeled secondary antibody: (goat anti-mouse (1 : 10 000), Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) and donkey anti-rabbit (1 : 3000), (Amersham, Buckinghamshire, England). The immuno-labeled proteins were visualized using enhanced chemiluminescent assays, ECL (Amersham, Buckinghamshire, England). For positive control immunoblotting experiments, ER-a and ER-b protein was commercially available (Anity BioReagents, Inc., Golden, CO, USA), and the breast cancer the poorly dierentiated and hormone resistant phenotype of MMMTs. This loss of total PR expression is consistent with previous studies which have reported a decrease in PR expression in poorly dierentiated endometrial cancers (Soper et al., 1984) , and may be an indication of the lack of hormone responsiveness in these tumors. Alternatively, the lack of response to hormonal therapy in MMMTs may be related to alterations in other molecular pathways such as p53 mutation which is seen in 66% of these tumors (Costa et al., 1994) but is infrequently identi®ed in well-dierentiated adenocarcinomas (Sherman, 2000) .
The mechanisms by which perturbations of steroid receptor subtype expression in¯uence neoplasia remain unknown. Estrogen receptor subtypes have opposing eects on AP-1 directed transcription (Paech et al., 1997) which may be a signi®cant pathway for ER action in the uterus (Webb et al., 1995) . However, the role for each transcriptional pathway and the ER subtypes in endometrial cell proliferation is unknown. Future investigation of this pathway will further our understanding of ER-a and ER-b actions in the human endometrium.
